CLINDESSE Drug Patent Profile
✉ Email this page to a colleague
When do Clindesse patents expire, and when can generic versions of Clindesse launch?
Clindesse is a drug marketed by Padagis Us and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-two patent family members in fourteen countries.
The generic ingredient in CLINDESSE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindesse
A generic version of CLINDESSE was approved as clindamycin phosphate by ALMAJECT on July 24th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLINDESSE?
- What are the global sales for CLINDESSE?
- What is Average Wholesale Price for CLINDESSE?
Summary for CLINDESSE
International Patents: | 22 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 1 |
Patent Applications: | 2,341 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CLINDESSE |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CLINDESSE |
What excipients (inactive ingredients) are in CLINDESSE? | CLINDESSE excipients list |
DailyMed Link: | CLINDESSE at DailyMed |
![CLINDESSE drug patent expirations Drug patent expirations by year for CLINDESSE](/p/graph/s/t/CLINDESSE-patent-expirations.png)
![Drug Prices for CLINDESSE](/p/graph/drug-price/CLINDESSE.png)
![Drug Sales Revenue Trends for CLINDESSE](/p/graph/drug-sales-revenues/CLINDESSE.png)
Recent Clinical Trials for CLINDESSE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Actavis Inc. | Phase 3 |
Watson Laboratories, Inc. | Phase 3 |
Pharmacology for CLINDESSE
Drug Class | Lincosamide Antibacterial |
Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
Paragraph IV (Patent) Challenges for CLINDESSE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CLINDESSE | Vaginal Cream | clindamycin phosphate | 2% | 050793 | 1 | 2015-02-05 |
US Patents and Regulatory Information for CLINDESSE
CLINDESSE is protected by one US patents.
Patents protecting CLINDESSE
Pharmaceutical delivery system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL VAGINOSIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Padagis Us | CLINDESSE | clindamycin phosphate | CREAM;VAGINAL | 050793-001 | Nov 30, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLINDESSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Padagis Us | CLINDESSE | clindamycin phosphate | CREAM;VAGINAL | 050793-001 | Nov 30, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Padagis Us | CLINDESSE | clindamycin phosphate | CREAM;VAGINAL | 050793-001 | Nov 30, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Padagis Us | CLINDESSE | clindamycin phosphate | CREAM;VAGINAL | 050793-001 | Nov 30, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLINDESSE
See the table below for patents covering CLINDESSE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Africa | 200407535 | Bioadhesive drug delivery system | ⤷ Sign Up |
South Korea | 20080091794 | MEDICAMENT FOR TOPICAL USE | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2007079390 | ⤷ Sign Up | |
Canada | 2392473 | SYSTEME D'ADMINISTRATION DE MEDICAMENTS BIOADHESIF (BIOADHESIVE DRUG DELIVERY SYSTEM) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLINDESSE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1304992 | 2013/044 | Ireland | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
1304992 | CR 2013 00053 | Denmark | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 |
1304992 | 122013000081 | Germany | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |